2nd Quarter - Report

BROWN RUDNICK LLP for HOSPIRA, INC.

Period 2nd Quarter 2012 Filed Jul 18, 2012 Signed by Michael Lewan - Principal

Official filing
Firm
BROWN RUDNICK LLP
Client
HOSPIRA, INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen Stabenow(05-07)
HENRY W MENN Min SD & Counsel, Cmte on Vet Affairs (04)
RUSSELL CONWELL RING Intern, Rep. Paris (84); LA, Rep. Paris (85-86)

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2245 (112th), S. 296 (112th), H.R. 5651 (112th), S. 3187 (112th), S. 2295 (112th), S. 2516 (112th), H.R. 4332 (112th), H.R. 3026 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.